111 related articles for article (PubMed ID: 37286471)
1. Molecular and clinical correlates of HER3 expression highlights its potential role as a therapeutic target in melanoma.
Shteinman ER; Vergara IA; Rawson RV; Lo SN; Maeda N; Koyama K; da Silva IP; Long GV; Scolyer RA; Wilmott JS; Menzies AM
Pathology; 2023 Aug; 55(5):629-636. PubMed ID: 37286471
[TBL] [Abstract][Full Text] [Related]
2. Comparative investigation of cell cycle and immunomodulatory genes in mucosal and cutaneous melanomas: Preliminary data suggest a potential promising clinical role for p16 and the PD-1/PD-L1 axis.
Wrede N; Hoffmann I; Vollbrecht C; Koch I; Wolkenstein P; Klauschen F; Capper D; von Laffert M; Jurmeister P
Pathol Res Pract; 2022 Jan; 229():153689. PubMed ID: 34844086
[TBL] [Abstract][Full Text] [Related]
3. HER3 expression in cutaneous tumors.
Wimmer E; Kraehn-Senftleben G; Issing WJ
Anticancer Res; 2008; 28(2A):973-9. PubMed ID: 18507044
[TBL] [Abstract][Full Text] [Related]
4. Nodular primary cutaneous melanoma is associated with PD-L1 expression.
Giavina-Bianchi M; Giavina-Bianchi P; Sotto MN; Rodig S; Mihm M; Festa Neto C; Duncan LM; Kalil J
Eur J Dermatol; 2020 Aug; 30(4):352-357. PubMed ID: 32969795
[TBL] [Abstract][Full Text] [Related]
5. HER3 is a determinant for poor prognosis in melanoma.
Reschke M; Mihic-Probst D; van der Horst EH; Knyazev P; Wild PJ; Hutterer M; Meyer S; Dummer R; Moch H; Ullrich A
Clin Cancer Res; 2008 Aug; 14(16):5188-97. PubMed ID: 18698037
[TBL] [Abstract][Full Text] [Related]
6. Melanoma subtypes demonstrate distinct PD-L1 expression profiles.
Kaunitz GJ; Cottrell TR; Lilo M; Muthappan V; Esandrio J; Berry S; Xu H; Ogurtsova A; Anders RA; Fischer AH; Kraft S; Gerstenblith MR; Thompson CL; Honda K; Cuda JD; Eberhart CG; Handa JT; Lipson EJ; Taube JM
Lab Invest; 2017 Sep; 97(9):1063-1071. PubMed ID: 28737763
[TBL] [Abstract][Full Text] [Related]
7. JAK2, PD-L1, and PD-L2 (9p24.1) amplification in metastatic mucosal and cutaneous melanomas with durable response to immunotherapy.
Gupta S; Vanderbilt CM; Cotzia P; Arias Stella JA; Chang JC; Chen Y; Tang LH; DeLair DF; Yao J; Ladanyi M; Ross DS
Hum Pathol; 2019 Jun; 88():87-91. PubMed ID: 30236595
[TBL] [Abstract][Full Text] [Related]
8. ERBB1/2/3 Expression, Prognosis, and Immune Infiltration in Cutaneous Melanoma.
Liu S; Geng R; Lin E; Zhao P; Chen Y
Front Genet; 2021; 12():602160. PubMed ID: 33732282
[TBL] [Abstract][Full Text] [Related]
9. Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry.
Cho J; Ahn S; Yoo KH; Kim JH; Choi SH; Jang KT; Lee J
Invest New Drugs; 2016 Dec; 34(6):677-684. PubMed ID: 27491654
[TBL] [Abstract][Full Text] [Related]
10. Primary anorectal melanoma: clinical, immunohistology and DNA analysis of 43 cases.
Dodds TJ; Wilmott JS; Jackett LA; Lo SN; Long GV; Thompson JF; Scolyer RA
Pathology; 2019 Jan; 51(1):39-45. PubMed ID: 30497801
[TBL] [Abstract][Full Text] [Related]
11. Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade.
Buchbinder EI; Weirather JL; Manos M; Quattrochi BJ; Sholl LM; Brennick RC; Bowling P; Bailey N; Magarace L; Ott PA; Haq R; Izar B; Giobbie-Hurder A; Hodi FS
Cancer Med; 2021 Apr; 10(8):2627-2635. PubMed ID: 33724703
[TBL] [Abstract][Full Text] [Related]
12. Digital image analysis improves precision of PD-L1 scoring in cutaneous melanoma.
Koelzer VH; Gisler A; Hanhart JC; Griss J; Wagner SN; Willi N; Cathomas G; Sachs M; Kempf W; Thommen DS; Mertz KD
Histopathology; 2018 Sep; 73(3):397-406. PubMed ID: 29660160
[TBL] [Abstract][Full Text] [Related]
13. Adipophilin expression in cutaneous malignant melanoma is associated with high proliferation and poor clinical prognosis.
Fujimoto M; Matsuzaki I; Nishitsuji K; Yamamoto Y; Murakami D; Yoshikawa T; Fukui A; Mori Y; Nishino M; Takahashi Y; Iwahashi Y; Warigaya K; Kojima F; Jinnin M; Murata SI
Lab Invest; 2020 May; 100(5):727-737. PubMed ID: 31857696
[TBL] [Abstract][Full Text] [Related]
14. COX-2 expression positively correlates with PD-L1 expression in human melanoma cells.
Botti G; Fratangelo F; Cerrone M; Liguori G; Cantile M; Anniciello AM; Scala S; D'Alterio C; Trimarco C; Ianaro A; Cirino G; Caracò C; Colombino M; Palmieri G; Pepe S; Ascierto PA; Sabbatino F; Scognamiglio G
J Transl Med; 2017 Feb; 15(1):46. PubMed ID: 28231855
[TBL] [Abstract][Full Text] [Related]
15. Concordance of somatic mutation profiles (BRAF,NRAS, and TERT) and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples.
Yang S; Leone DA; Biswas A; Deng A; Jukic D; Singh R; Sundram U; Mahalingam M
Hum Pathol; 2018 Dec; 82():206-214. PubMed ID: 30120967
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitors' Response and Survival in Advanced Melanoma Patients in Brazil.
Sorroche BP; Teixeira RJ; Pereira CAD; Santana IVV; Vujanovic L; Vazquez VL; Arantes LMRB
Diagnostics (Basel); 2023 Mar; 13(6):. PubMed ID: 36980349
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive analysis of cutaneous and uveal melanoma liver metastases.
Hoefsmit EP; Rozeman EA; Van TM; Dimitriadis P; Krijgsman O; Conway JW; Pires da Silva I; van der Wal JE; Ketelaars SLC; Bresser K; Broeks A; Kerkhoven RM; Reeves JW; Warren S; Kvistborg P; Scolyer RA; Kapiteijn EW; Peeper DS; Long GV; Schumacher TNM; Blank CU
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33262254
[TBL] [Abstract][Full Text] [Related]
18. eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma.
Chen X; Wang K; Jiang S; Sun H; Che X; Zhang M; He J; Wen Y; Liao M; Li X; Zhou X; Song J; Ren X; Yi W; Yang J; Chen X; Yin M; Cheng Y
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35347072
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma.
Fröhlich A; Loick S; Bawden EG; Fietz S; Dietrich J; Diekmann E; Saavedra G; Fröhlich H; Niebel D; Sirokay J; Zarbl R; Gielen GH; Kristiansen G; Bootz F; Landsberg J; Dietrich D
EBioMedicine; 2020 Feb; 52():102647. PubMed ID: 32028068
[TBL] [Abstract][Full Text] [Related]
20. NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors.
Thielmann CM; Chorti E; Matull J; Murali R; Zaremba A; Lodde G; Jansen P; Richter L; Kretz J; Möller I; Sucker A; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Mohr P; Gutzmer R; Meier F; Dippel E; Weichenthal M; Paschen A; Livingstone E; Zimmer L; Schadendorf D; Hadaschik E; Ugurel S; Griewank KG
Eur J Cancer; 2021 Dec; 159():113-124. PubMed ID: 34742158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
